title: Evaluation of patients with liver metastases from colorectal cancer for locally ablative treatment with laser induced thermotherapy. Impact of PET with 18F-fluorodeoxyglucose on therapeutic decisions.
abstract: OBJECTIVE
  Before locally ablative treatment of colorectal liver metastases, patients have to be carefully evaluated to decide whether this is the adequate therapy. In this study we determined the value of FDG-PET in comparison to conventional staging procedures.
  
  
  METHODS
  In 68 consecutive patients referred for laser induced thermotherapy (LITT) of liver metastases from colorectal cancer, pretherapeutic staging with conventional imaging (thoracic and abdominal CT, liver MRI, chest X-ray) and FDG-PET was performed. The examinations were analysed separately and blinded. Based on the staging information, therapeutic decisions were made by an interdisciplinary review board according to a standardized algorithm. The results were compared between conventional imaging and FDG-PET, and were validated by clinical follow up data and histopathology, respectively.
  
  
  RESULTS
  On FDG-PET 210 lesions were interpreted as tumour manifestations. 48 of these were not seen on conventional imaging (true positive, n = 46). In contrast, 24 lesions were visualized by conventional imaging only (true positive, n = 12). Compared to conventional imaging, discrepant findings on FDG-PET led to treatment modifications in 25 patients (37%); these were correct in 20/25 patients. According to the actual treatment course, the inadequate treatment modifications in the remaining 5 patients were avoided by further diagnostic procedures (i.e. biopsies).
  
  
  CONCLUSIONS
  In the evaluation of patients with known liver metastases from colorectal cancer before LITT, FDG-PET depicts relevant findings subsidiary to conventional imaging and thus is of high value for therapeutic decision making.
authors.affiliation: Klinik für Strahlenheilkunde, Charité-Universitätsmedizin, Augustenburger Platz 1, 13353 Berlin, Germany. h.amthauer@charite.de
authors.forename: H
authors.initials: H
authors.lastname: Amthauer
authors.forename: T
authors.initials: T
authors.lastname: Denecke
authors.forename: B
authors.initials: B
authors.lastname: Hildebrandt
authors.forename: R
authors.initials: R
authors.lastname: Rühl
authors.forename: A
authors.initials: A
authors.lastname: Miersch
authors.forename: A
authors.initials: A
authors.lastname: Nicolaou
authors.forename: J
authors.initials: J
authors.lastname: Ruf
authors.forename: M
authors.initials: M
authors.lastname: Plotkin
authors.forename: E L
authors.initials: EL
authors.lastname: Hänninen
authors.forename: C
authors.initials: C
authors.lastname: Stroszczynski
authors.forename: M
authors.initials: M
authors.lastname: Gutberlet
authors.forename: J
authors.initials: J
authors.lastname: Langrehr
authors.forename: H
authors.initials: H
authors.lastname: Riess
authors.forename: J
authors.initials: J
authors.lastname: Ricke
mesh_terms: D015179:Colorectal Neoplasms / Q000473:pathology*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D006979:Hyperthermia, Induced; D007834:Lasers; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary / Q000601:surgery* / Q000628:therapy*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18